ProCE Banner Activity

Selecting Treatment for HER2-Low/Ultralow mBC After Progression on ET

Slideset

Download these slides from an ASCO 2025 live satellite symposium on selecting treatment for HER2-low/ultralow metastatic breast cancer following progression on standard endocrine therapy. 

Released: May 22, 2025

Expiration: November 21, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.